Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Zai Lab Limited is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for oncology, autoimmune, infectious disease, and neuroscience indications. The company operates within the biopharmaceutical and life sciences industries, with an emphasis on addressing significant unmet medical needs through both in-licensed and internally developed therapies. Zai Lab generates revenue primarily through product sales of approved medicines in Greater China, as well as milestone payments and collaborations with global pharmaceutical partners.
Founded in 2014, Zai Lab has evolved from a China-focused licensing and commercialization platform into an integrated biopharmaceutical company with global research, development, and manufacturing capabilities. The company’s strategy combines late-stage in-licensing of global assets with internal research and development, enabling faster market entry while building long-term innovation capabilities. Its unique positioning lies in its deep regulatory, clinical, and commercial expertise in China, coupled with expanding international operations.
Business Operations
Zai Lab operates through several core business segments, primarily centered on Oncology, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Neuroscience. Revenue is largely generated from the commercialization of approved products such as ZEJULA (niraparib), OPTUNE, VYVGART, and NUZYRA, as well as collaboration-related income. The company manages end-to-end operations including clinical development, regulatory approval, manufacturing oversight, and commercial distribution.
The company maintains a combination of internal capabilities and strategic partnerships. Zai Lab controls proprietary research assets through its internal R&D organization and operates manufacturing facilities in China, while also leveraging contract manufacturing organizations. It has ongoing collaborations with multiple global biopharmaceutical companies, and operates through wholly owned subsidiaries including Zai Lab (Shanghai) Co., Ltd. and Zai Lab (Suzhou) Co., Ltd., which support research, manufacturing, and commercialization activities.
Strategic Position & Investments
Zai Lab’s strategic direction emphasizes sustainable growth through pipeline expansion, lifecycle management of commercial products, and selective global development of internally discovered assets. The company has made significant investments in building its own research engine, particularly in oncology and immunology, while continuing to in-license differentiated late-stage or approved products with strong clinical data.
Notable investments include the acquisition of Deciphera Pharmaceuticals China rights and the expansion of internal discovery programs in small molecules and biologics. Zai Lab has also invested heavily in clinical infrastructure and manufacturing capabilities to support long-term growth. Emerging areas of focus include novel oncology targets, autoimmune therapies, and next-generation biologics, with several assets in global clinical development. Where disclosures differ on future commercial scope outside China, data inconclusive based on available public sources.
Geographic Footprint
Zai Lab is headquartered in China, with its principal executive offices in Shanghai. The company’s primary commercial and clinical operations are concentrated in Greater China, including mainland China, Hong Kong, and Taiwan. Manufacturing and research facilities are located in multiple Chinese cities, supporting domestic supply and development activities.
Internationally, Zai Lab has established a growing presence in the United States and Europe, primarily focused on research and global clinical development. The company conducts multinational clinical trials and maintains offices in the United States, enabling engagement with global regulators, partners, and investors. Its international footprint supports its strategy of advancing select assets beyond China while remaining China-centric in commercialization.
Leadership & Governance
Zai Lab was founded by Samantha Du, who continues to play a central role in shaping the company’s long-term vision. The leadership team emphasizes scientific rigor, patient-centric development, and disciplined capital allocation, with a governance structure aligned to global biopharmaceutical standards as a U.S.-listed company.
Key executives include:
- Samantha Du – Founder, Chairperson, and Chief Executive Officer
- Josh Smiley – Chief Operating Officer
- Ying Huang – Chief Financial Officer
- Jonathan Wang – Chief Legal Officer
- Jamie Freedman – Chief Medical Officer
The leadership philosophy centers on integrating global innovation with local execution excellence, aiming to build Zai Lab into a sustainable, research-driven biopharmaceutical leader with global impact.